Some GLP-1 patients are begging to stay on the drugs just a little bit longer, presenting an ethical dilemma for doctors.
A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, ...
Soaring in popularity, GLP-1 medications—from weekly injections to newly available pills—are rapidly reshaping how Americans ...
Medications for obesity may improve fertility, but there are many unknowns when it comes to using them during pregnancy.
Although Super Bowl LX’s ad lineup had plenty of the usual beer, car and tech company pitches, drug and other healthcare companies also shelled out $8 million for a 30-second spot to send their ...
A $350 genetic test developed by researchers at Mayo Clinic in Rochester, Minn., and subsequently licensed to Phenomic Sciences, seeks to assign risk scores to patients regarding their likelihood of ...
Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...
Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with addiction, Martin Holst Lange, the Danish pharma’s head of development, told an ...
For now, GLP-1 drugs remain a powerful tool for diabetes and obesity, with the potential to become much more. As research ...
Noom on Thursday announced it is offering users access to compounded semaglutide as part of a new weight loss product starting at $149. The digital health company already offers branded GLP-1s through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results